Press Releases | Medtronic

Month Year

Email alerts

May 8, 2012

Medtronic Expands Availability of Valiant(R) Captivia(R) Stent Graft in Major Global Markets

Implantable Medical Device for Endovascular Repair of Thoracic Aortic Aneurysms Also Being Studied for Minimally Invasive Treatment of Blunt Thoracic Aortic Injuries

MINNEAPOLIS--(BUSINESS WIRE)--May. 8, 2012-- Increasing patient access to endovascular repair of aortic aneurysms worldwide, Medtronic, Inc. (NYSE: MDT) is expanding availability of the Valiant®...
Apr 30, 2012

Eighteen North Suburban High School Graduates Named 2012 Medtronic Scholars

Medtronic Foundation has committed nearly $1.5 million in local scholarships.

MINNEAPOLIS--(BUSINESS WIRE)--Apr. 30, 2012-- The Medtronic Foundation today announced that 18 students have been selected as 2012 Medtronic Scholars. Each will receive a four-year scholarship...
Apr 27, 2012

Trial of Medtronic Symplicity(TM) Renal Denervation System Shows Significant Blood Pressure Reduction, With No Evidence of Renal Impairment, at Six Months Post Treatment

Six Month Pooled Outcomes From Randomized and Crossover Patients Following Renal Denervation Presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension Confirm Previous Symplicity Clinical Trial Findings

MINNEAPOLIS & LONDON, Apr 27, 2012 (BUSINESS WIRE) --Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical...
Apr 24, 2012

Medtronic Named One of America's Best Corporate Citizens

Medical Technology Leader Ranked in Top 50 on Corporate Responsibility Magazine's 100 Best Corporate Citizens List

MINNEAPOLIS, Apr 24, 2012 (BUSINESS WIRE) --Medtronic, Inc. is one of America's best corporate citizens, according to the rankings recently released by Corporate Responsibility magazine. Medtronic...
Apr 17, 2012

Medtronic Announces Global Drug-Eluting Balloon Study

International Research Program Will Collect and Assess Safety and Efficacy Data on IN.PACT Admiral(TM) Drug-Eluting Balloon in Treatment of Peripheral Artery Disease

MINNEAPOLIS & LONDON, Apr 17, 2012 (BUSINESS WIRE) --In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. (NYSE:...
Apr 16, 2012

Medtronic Endurant(R) AAA Stent Graft Shows Durable Performance at Two Years in U.S. Study

Market-Leading Medical Device for Minimally Invasive Treatment of Abdominal Aortic Aneurysms Continues to Demonstrate Strong Safety and Efficacy

MINNEAPOLIS & LONDON, Apr 16, 2012 (BUSINESS WIRE) --Bolstering confidence in endovascular repair of abdominal aortic aneurysms (AAA), Medtronic Inc. (NYSE:MDT) announced yesterday the two-year...
Apr 16, 2012

Medtronic Announces Launch of the POWEREASE(TM) System

Latest innovation offers power technology for reconstructive spine surgery

MEMPHIS, Tenn., Apr 16, 2012 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced the initiation of its launch of the POWEREASE(TM) System, an innovative system of electronic instruments...
Apr 13, 2012

Medtronic Initiates Landmark U.S. Drug-Eluting Balloon Study

First Patients Treated in Clinical Trial of Novel Medical Device Involving Interventions for Lower-Extremity Peripheral Artery Disease

MINNEAPOLIS, Apr 13, 2012 (BUSINESS WIRE) --Expanding its commitment to developing innovative treatments for cardiovascular disease and the evidence to support their adoption, Medtronic, Inc....
Apr 13, 2012

Medtronic Foundation Launches Online Save-a-Life Simulation to Promote Bystander Response for Cardiac Arrest

Interactive Tool Simulates Sudden Cardiac Arrest Event; Teaches Crucial Steps in Saving a Life

MINNEAPOLIS, Apr 13, 2012 (BUSINESS WIRE) --The Medtronic Foundation's HeartRescue Project has produced an interactive, online experience, the "Save-a-Life Simulator," to promote proper and timely...
Apr 10, 2012

Medtronic Receives FDA Approval to Treat Mildly Symptomatic Heart Failure Patients Through Expanded Indication for CRT-D

Pivotal REVERSE & Landmark RAFT Clinical Trials Demonstrate Reduction in Mortality and Heart Failure Hospitalization Rates in New Patient Population

MINNEAPOLIS--(BUSINESS WIRE)--Apr. 10, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for its cardiac...
Mar 30, 2012

Medtronic Reaches Settlement of Shareholder Class Action

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 30, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that the company has reached an agreement in principle to settle a previously disclosed federal securities...
Mar 26, 2012

Medtronic-Sponsored Study Finds Pacemakers Reduce Fainting in Patients

ACC.12 Late-breaker Shows Promise of Pacemakers through Diminishing Fainting Recurrences in Patients Diagnosed with Syncope

MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 26, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered...
Mar 25, 2012

Medtronic Symplicity™ Renal Denervation System Demonstrates Significant and Sustained Blood Pressure Reduction out to Three Years

Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years

MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 25, 2012-- Medtronic, Inc. (NYSE:MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood...
Mar 24, 2012

Data Presented at ACC Reinforce Positive Clinical Outcomes for Patients Receiving Medtronic’s CoreValve® System

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic...
Mar 24, 2012

Medtronic Resolute® Drug-Eluting Stent Delivers Durable Clinical Outcomes Through Two Years in Major Studies

Recently FDA-Approved, Novel Heart Device Shows Consistently Low Event Rates Across Broad Spectrum of Coronary Artery Disease Patients, Including Those with Diabetes

CHICAGO--(BUSINESS WIRE)--Mar. 24, 2012-- According to new clinical data presented today at ACC.12 –– the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC)...
Mar 15, 2012

Medtronic Receives Health Canada License for Deep Brain Stimulation Therapy in Refractory Epilepsy Patients

Another Medtronic First in Neuromodulation in Canada

BRAMPTON, Ontario & MINNEAPOLIS--(BUSINESS WIRE)--Mar. 15, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation...
Mar 14, 2012

Medtronic Announces Public Offering of Senior Notes

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 14, 2012-- Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $675 million of its 3.125% Senior Notes due 2022 and $400 million of its 4.50%...
Mar 7, 2012

Medtronic CFO Gary Ellis to Speak at Barclays Capital Global Healthcare Conference

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 7, 2012-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Barclays Capital Global...
Mar 5, 2012

Medtronic Receives CE Mark for Pacemaker Lead That Will Expand Patient Access to MRI Technology

CapSure Sense MRI™ SureScan® Passive Fixation Leads Gives Physicians More MR-Conditional Options

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 5, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the receipt of CE Mark (Conformité Européenne) and launch of the CapSure Sense MRI™ SureScan® pacing...
Mar 1, 2012

Medtronic Seeking Long-Distance Runners Who Benefit from Medical Technology

“Global Heroes” Will Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 1, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it is recruiting runners from around the world who benefit from medical technology to participate in the...
Feb 29, 2012

Study of Next Step Toward Artificial Pancreas from Medtronic Meets Efficacy Endpoints

World’s First Insulin Pump with Low Glucose Suspend Showed Reduces Time Spent in Low Threshold Range

MINNEAPOLIS--(BUSINESS WIRE)--Feb. 29, 2012-- In the next step toward the development of an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced that the results of the in-clinic ASPIRE...
Feb 23, 2012

Medtronic CFO Gary Ellis to Speak at Citi Healthcare Conference

MINNEAPOLIS--(BUSINESS WIRE)--Feb. 23, 2012-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Citi Healthcare Conference...
Feb 21, 2012

Medtronic Reports Third Quarter Earnings

Revenue of $3.9 Billion Driven by International Revenue Growth of 6% on a Constant Currency Basis, 7% as Reported

MINNEAPOLIS--(BUSINESS WIRE)--Feb. 21, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2012, which ended January 27, 2012. The company...
Feb 17, 2012

Medtronic Resolute Integrity Drug-Eluting Stent Obtains FDA Approval for Treating Coronary Artery Disease

Distinguished by Superior Deliverability and Diabetes Indication, New Heart Device Becomes Available to Cath Labs Nationwide

MINNEAPOLIS--(BUSINESS WIRE)--Feb. 17, 2012-- Advancing the clinical practice of interventional cardiovascular medicine, Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (
Feb 16, 2012

Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2012

MINNEAPOLIS--(BUSINESS WIRE)--Feb. 16, 2012-- The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.2425 per share of the Company’s common stock. The dividend...

Show per page